Dublin, Ireland, 18th December 2018 – Afimmune, a privately held clinical stage drug discovery and development company, today announced receipt of allowance for a patent application in the United States of America (US). The allowance protects the use of the Company’s lead compound AF102 (15-HEPE) in a number of conditions affecting human primary organs including the liver and the lung.
The United States Patent and Trademark Office (USPTO) has allowed the patent application entitled “Compositions comprising 15-HEPE and methods of using the same” with serial number 15/841,363 to grant. This patent will provide exclusivity for broad method of use claims protecting AF102 for inhibiting and relieving conditions such as fibrotic and inflammatory disorders. These claims will be protected until 2036 in the US.
Mr. Tien Nghiem, Director of Product Development and Intellectual Property at Afimmune commented: “The allowance of this patent further strengthens the AF102 patent portfolio which includes granted patents in the US, Europe as well as other jurisdictions. Afimmune continues to prosecute other patent applications for AF102.”
Afimmune, headquartered in Dublin, Ireland, is a clinical stage drug discovery and development company working on inflammatory conditions of the human primary organs including the liver and the lung. Afimmune has three separate Phase 2 trials ongoing at present exploring the therapeutic effect of AF102 in patients with non-alcoholic fatty liver disease (NAFLD), Alcoholic Hepatitis (AH) and chronic obstructive pulmonary disease (COPD). AF102 has been granted Fast Track Designation as an investigational treatment for patients suffering from NASH (Non-Alcoholic Steatohepatitis) with liver fibrosis by the US Food and Drug Administration (FDA).